Anidulafungin

Brands

DEA Class; Rx

Common Brand Names; Eraxis

  • Antifungals, Systemic; 
  • Antifungals, Echinocandin

IV echinocandin antifungal drug
Used for candidemia and other invasive candidiasis infections and esophageal and oropharyngeal candidiasis
Efficacy for treatment of infections caused by fungi other than Candida has not been established

Indicated for treatment of candidemia and intra-abdominal abscess and peritonitis caused by Candida infections
Indicated for treatment of esophageal candidiasis
Based on the limited data, an echinocandin drug (eg, anidulafungin, caspofungin, micafungin) is recommended by the CDC as initial therapy for treatment of C auris infections

Hypersensitivity to any component or other echinocandins

Known or suspected hereditary fructose intolerance

Adults (candidemia)

  • Hypokalemia (25%)
  • Nausea (24%)
  • Diarrhea (18%)
  • Pyrexia (18%)
  • Hypotension (15%)
  • Insomnia (15%)
  • Hypertension (12%)
  • Dyspnea (12%)
  • Increased alkaline phosphatase (12%)
  • Hypomagnesemia (12%)
  • Peripheral edema (11%)

Pediatric (candidemia)

  • Pyrexia (18%)
  • Diarrhea (16%)
  • Vomiting (16%)

Abnormal LFTs observed; if elevated liver tests develop, monitor for evidence of worsening hepatic tests and evaluate risk benefit of continuing anidulafungin monitor for potential hepatic problems

Anaphylactic reactions, including shock, reported; discontinue and initiate appropriate treatment if this occurs

Infusion-related adverse reactions (possibly histamine-mediated) reported, including rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension; reduce risk by not exceeding recommended infusion rate

Contains polysorbate 80, an inactive ingredient; thrombocytopenia, renal dysfunction, hepatomegaly, cholestasis, ascites, hypotension, and metabolic acidosis reported in low-birth weight infants receiving high doses of polysorbate; toxicity has not been reported with anidulafungin

Contains fructose; may precipitate a metabolic crisis (eg, life-threatening hypoglycemia, hypophosphatemia, lactic acidosis, hepatic failure) in patients with hereditary fructose intolerance

Based on findings from animal studies, therapy can cause fetal harm when administered to pregnant females; there are no available human data on use in pregnant females to inform a drug-associated risk of adverse developmental outcomes

There are no data on presence of drug in human milk, effects on breastfed infant or on milk production

Adults

200 mg/day IV for loading dose; 100 mg/day IV for maintenance.

Geriatric

200 mg/day IV for loading dose; 100 mg/day IV for maintenance.

Adolescents

3 mg/kg IV (Max: 200 mg/dose) for loading dose; 1.5 mg/kg/day IV (Max: 100 mg/day) for maintenance dose.

Children

3 mg/kg IV (Max: 200 mg/dose) for loading dose; 1.5 mg/kg/day IV (Max: 100 mg/day) for maintenance dose.

Infants

3 mg/kg IV for loading dose; 1.5 mg/kg/day IV for maintenance dose.

Neonates

Safety and efficacy have not been established; however, 3 mg/kg IV as a loading dose and 1.5 mg/kg/day IV as a maintenance dose have been used off-label.

Anidulafungin

injection, lyophilized powder for reconstitution

  • 50mg/vial
  • 100mg/vial
Drugs Generic
Tags ,

About the Author

postblaze

You may also like these

0